

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Rifamycin. [Updated 2019 Apr 1]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Rifamycin

Revised: April 1, 2019.

CASRN: 6998-60-3

Drug Levels and Effects

Summary of Use during Lactation

Rifamycin is negligibly absorbed orally and used only for gastrointestinal infections. It is not likely to reach the breastmilk or bloodstream of the infant or cause any adverse effects in breastfed infants after maternal use.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Rifamycin

CAS Registry Number

6998-60-3

Drug Class

Anti-Infective Agents

Gastrointestinal Agents

Rifamycins